Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study

Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery. The LYNX-2 trial is being conducted under conditions of a Special Protocol Assessment with the U.S. Food and Drug Administration. As previously announced, Ocuphire received written agreement from the FDA that the clinical trial protocol and planned statistical analysis of the LYNX-2 Phase 3 trial would adequately address objectives supporting regulatory submission and a potential future marketing application in this indication.